VIGENCELL INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,765 KRW | 0.00% |
|
+2.92% | -18.55% |
| 2023 | ViGenCell Inc.(KOSDAQ:A308080) dropped from S&P Global BMI Index | CI |
| 2023 | ViGenCell Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 112B 154,328B |
|---|---|---|---|---|---|
| Net income 2022 | -17.39B -23,941B | Net income 2023 | -17.88B -24,604B | EV / Sales 2022 | - |
| Net cash position 2022 | 61.66B 84,878B | Net cash position 2023 | 45.96B 63,265B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-7.77
x | P/E ratio 2023 |
-6.24
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.4% |
More Fundamentals
* Assessed data
| 1 week | +2.92% | ||
| Current month | -6.93% | ||
| 1 month | -7.12% | ||
| 3 months | -6.57% | ||
| 6 months | +0.53% | ||
| Current year | -18.55% |
1 week
4 605.00
4 800.00
1 month
4 510.005 240.00
Current year
4 510.006 190.00
1 year
4 510.007 900.00
3 years
4 510.0039 000.00
5 years
4 510.0039 000.00
10 years
4 510.0039 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Tae Gyu Kim
CEO | Chief Executive Officer | 66 | - |
Hyun-Jung Son
BRD | Director/Board Member | 51 | - |
Kyung-Muk Kim
BRD | Director/Board Member | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Su-Hui Park
BRD | Director/Board Member | 64 | - |
Kyung-Muk Kim
BRD | Director/Board Member | 55 | - |
Tae Gyu Kim
CEO | Chief Executive Officer | 66 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4,765 | 0.00% | 12,126 |
| 24-04-25 | 4,765 | 0.00% | 16,067 |
| 24-04-24 | 4,765 | +3.03% | 17,351 |
| 24-04-23 | 4,625 | 0.00% | 11,925 |
| 24-04-22 | 4,625 | -0.11% | 15,688 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
ViGenCell Inc is a Korea-based company principally engaged in the development of cell therapy business. The Company is engaged in the development and manufacture of immuno-cancer cell therapy products and immunosuppressive cell therapy products. In addition, the Company is engaged in the provision of vitier platform as an antigen-specific killing t cell treatment, viranger platform as a gammadelta t cell gene therapy and vimedier platform-based technology as a myeloid suppressor cell therapy derived from umbilical cord blood. It is engaged in the research and development of new drugs such as acute myeloid leukemia (AML) and glioblastoma.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.55% | 66.49M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- A308080 Stock
